Safety of Tenofovir Alafenamide in People With HIV Who Experienced Proximal Renal Tubulopathy on Tenofovir Disoproxil Fumarate-Reference-Cited by-同舟云学术

Safety of Tenofovir Alafenamide in People With HIV Who Experienced Proximal Renal Tubulopathy on Tenofovir Disoproxil Fumarate

Published:2021-10-01 Issue:2 Volume:88 Page:214-219
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Campbell Lucy,Barbini Birgit,Burling Keith,Cromarty Ben,Hamzah Lisa,Johnson Margaret,Jones Rachael,Samarawickrama Amanda,Williams Deborah,Winston Alan,Post Frank A.,

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference32 articles.

1. Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity;Yombi;AIDS.,2014

2. Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?;Tourret;J Am Soc Nephrol.,2013

3. Association of tenofovir exposure with kidney disease risk in HIV infection;Scherzer;AIDS.,2012

4. Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure;Jose;J Infect Dis.,2014

5. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study;Mocroft;Lancet HIV.,2016

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety of tenofovir alafenamide in people with HIV who experienced proximal renal tubulopathy on tenofovir disoproxil;AIDS;2024-06-27

2. Renal safety of tenofovir alafenamide-based antiretroviral therapy in people with HIV: A mini-review;BioScience Trends;2024-04-30

3. Delayed Irreversible Fanconi Syndrome Associated With Vertebral Fracture After Tenofovir Discontinuation;Cureus;2024-01-31

4. Real-life data of immune recovery using bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV. Results at 48–96 weeks of RETROBIC Study;Journal of Antimicrobial Chemotherapy;2024-01-24

5. Fanconi Syndrome in Patients With Human Immunodeficiency Virus Treated With Tenofovir-Based Antiretroviral Therapy: A Systematic Literature Review;Annals of Pharmacotherapy;2023-11-06